Some of the most commonly used adjuvants are oil in water nano-emulsions. These adjuvants are ideal for pandemic vaccines because their antibody response and safety is well understood.
MF59, which has been approved for the flu vaccine, has been developed for pandemic vaccines by the Infectious Disease Research Institute and others. These adjuvants can be produced quickly, and can greatly increase the efficacy of the vaccine while limiting the quantity of antigen that is required per dose. The high shear rates and uniform processing generated by Microfluidizer® technology enables sterile filtration of emulsions at production scales.
Many other types of recombinant molecules are processed with Microfluidizer® technology. Any recombinant process that requires cell disruption will benefit from consistent processing which will enable cell disruption at the lowest energy levels possible. Low input energy and efficient cooling ensures that the molecules that are being produced have the highest chance of maintaining activity.
Our line of cGMP processors ensures that the products are made in an environment that will allow for very quick vaccine adjuvant production from the time of order.
For future reading please visit